Frag 17-23
HGH fragment 176-191 variant
A short sub-fragment of HGH's lipolytic tail.
Half-life
~ hours
Mol. weight
Varies (short sub-fragment)
Sequence
HGH C-terminal sub-fragment variant
Discussions
0 threads
Overview
Frag 17-23 is a short variant sub-fragment of the HGH 176-191 lipolytic region, researched for its potential fat-metabolism effects as an even shorter alternative to AOD-9604. Evidence is largely preclinical and limited.
Mechanism of action
Frag 17-23 is a truncated version of the C-terminal lipolytic region of human growth hormone, studied for its potential to stimulate lipolysis via the same beta-adrenergic-like pathways targeted by longer HGH fragments — with even less supporting clinical data than AOD-9604.
Researched benefits
- Targets the lipolytic region of HGH
- Even shorter alternative to AOD-9604
- Studied for fat-metabolism effects in vitro
Considerations
- Very limited evidence; mostly in vitro
- Fragment of a fragment — potency concerns
- Not FDA-approved; research context only
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating Frag 17-23 in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on Frag 17-23:
View Frag 17-23 index on PubMed (NCBI)